

7 April 2022

Diaceutics PLC
("Diaceutics" or "the Company")

Purchase and Sale of Shares and PDMR Shareholdings

[Diaceutics PLC](#), (AIM: DXRX), the diagnostic commercialisation company announces the following Director and PDMR share dealings.

On 5 April 2022, Nick Roberts, CFO of Diaceutics, purchased 39,179 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of £1.015 pence per Ordinary Share. As a result of the purchase, Nick's shareholding is 39,179 Ordinary Shares, representing approximately 0.05 % of the Company's issued share capital.

On 6 April 2022, Deborah Davis, the Chair of Diaceutics, purchased 20,000 Ordinary Shares at an average price of £1.0125 pence per share. As a result of the purchase, Deborah's shareholding is 64,800 Ordinary Shares, representing approximately 0.08 % of the Company's issued share capital.

On 6 April 2022, Charles Hindson, Non-Executive Director of Diaceutics, purchased 20,000 Ordinary Shares at a price of £1.01 pence per share. As a result of the purchase, Charles' shareholding is 63,500 Ordinary Shares, representing approximately 0.08 % of the Company's issued share capital.

Across 5 and 6 April 2022, Philip White, a PDMR, sold 200,000 Ordinary Shares at an average price of £0.989 pence per Ordinary Share. As a result of Philip's sale, the beneficial holding of Philip White and his connected parties in the Company is 1,406,389 Ordinary Shares, representing 1.67 % of the Company's issued share capital.

Enquiries:

Diaceutics PLC

Nick Roberts, Chief Financial Officer

Via Alma PR

Stifel Nicolaus Europe Limited (Nomad & Broker)

Tel: +44 (0)20 7710 7600

Ben Maddison
Stewart Wallace
Nick Adams

Alma PR

Caroline Forde
Kieran Breheny
Matthew Young

Tel: +44(0)20 3405 0205
diaceutics@almapr.co.uk

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	Nick Roberts
2 Reason for notification		

a.	Position/Status	CFO				
b.	Initial notification/ Amendment	Initial				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Purchase				
c.	Price(s) and volume(s)	Share purchase: <table border="1" data-bbox="531 826 976 965"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£1.015</td> <td>39,179</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£1.015	39,179
Price(s)	Volume(s)					
£1.015	39,179					
d.	Date of the transaction	5 April 2022				
e.	Place of the transaction	AIM Market of the London Stock Exchange				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1	Details of the person discharging managerial responsibilities/person closely associated	
a.	Name	Deborah Davis
2	Reason for notification	
a.	Position/Status	Chair
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTGV64
b.	Nature of the transaction	Purchase

c.	Price(s) and volume(s)	Share purchase: <table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£1.01</td> <td>15,000</td> </tr> <tr> <td>£1.02</td> <td>5,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£1.01	15,000	£1.02	5,000
Price(s)	Volume(s)							
£1.01	15,000							
£1.02	5,000							
d.	Date of the transaction	6 April 2022						
e.	Place of the transaction	AIM Market of the London Stock Exchange						

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014						
1 Details of the person discharging managerial responsibilities/person closely associated						
a.	Name	Charles Hindson				
2 Reason for notification						
a.	Position/Status	Non-Executive Director				
b.	Initial notification/ Amendment	Initial				
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Purchase				
c.	Price(s) and volume(s)	Share purchase: <table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£1.01</td> <td>20,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£1.01	20,000
Price(s)	Volume(s)					
£1.01	20,000					
d.	Date of the transaction	6 April 2022				
e.	Place of the transaction	AIM Market of the London Stock Exchange				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014								
1 Details of the person discharging managerial responsibilities/person closely associated								
a.	Name	Philip White						
2 Reason for notification								
a.	Position/Status	PDMR						
b.	Initial notification/ Amendment	Initial						
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor								
a.	Name	Diaceutics PLC						
b.	LEI	213800VEWQBB39ZB8J81						
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted								
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 ISIN: GB00BJQTGV64						
b.	Nature of the transaction	Sale						
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£1.01</td> <td>60,000</td> </tr> <tr> <td>£0.98</td> <td>140,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£1.01	60,000	£0.98	140,000
Price(s)	Volume(s)							
£1.01	60,000							
£0.98	140,000							
e.	Date of the transaction	5 & 6 April 2022						
f.	Place of the transaction	AIM Market of the London Stock Exchange						

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFLFIASFIRIIF